Research Article

Optimal Treatment Strategies for HIV with Antibody Response

Yinggao Zhou,¹ Kuan Yang,² Kai Zhou,¹ and Chunling Wang¹

¹ School of Mathematics and Statistics, Central South University, Changsha, Hunan 410083, China

² School of Business Administration, Hunan University, Changsha, Hunan 410082, China

Correspondence should be addressed to Kuan Yang; yangkuan@hnu.edu.cn

Received 21 April 2014; Revised 6 June 2014; Accepted 24 June 2014; Published 10 July 2014

Academic Editor: Zhen Jin

Copyright © 2014 Yinggao Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Numerical analysis and optimization tools are used to suggest improved therapies to try and cure HIV infection. An HIV model of ordinary differential equation, which includes immune response, neutralizing antibodies, and multidrug effects, is improved. For a fixed time, single-drug and two-drug treatment strategies are explored based on Pontryagin's maximum principle. Using different combinations of weight factor pairs combining with special upper-bound pairs for controls, nine types of treatment policies are determined and different therapy effects are numerically simulated with a gradient projection method. Some strategies are effective, but some strategies are not particularly helpful for the therapy of HIV/AIDS. Comparing the effective treatment strategies, we find a more appropriate strategy with maximizing the number of uninfected CD4⁺T-cells and minimizing the number of active virus.

1. Introduction

Up to date, drug treatments are still available control methods of HIV/AIDS. Reverse transcriptase inhibitors (RTIs) can inhibit HIV RNA from being converted into DNA, thus blocking integration of the viral code into the target cell. Protease inhibitors (PIs) function by preventing the assembly of key viral proteins after they have been produced by the infected host cell. Therefore, PIs effectively reduce the number of infectious virus particles released by an infected cell. HAART consists of combined drug regimens that include two, or three, nucleoside agents alone or two nucleoside agents combined with a protease inhibitor, or a nonnucleoside reverse transcriptase inhibitor [1]. This paper explores the effects of a combination of a protease inhibitor and a nucleoside reverse transcriptase inhibitor.

Mathematical models are often used to study HIV/AIDS spread and host-drug-virus interactions to make assumptions and to suggest new methods for its optimal control. Zurakowski and Teel [2] developed a model to determine optimal treatment interruption schedules, simulate therapeutic vaccine, and induce Cytotoxic T Lymphocyte (CTL) mediated control of HIV infection. Karrakchou et al. [3] proposed an infectious model which described the interaction of HIV virus and the immune system of the human body to

investigate the fundamental role of chemotherapy treatment in controlling the virus reproduction and to determine the optimal methodology for administering antiviral medication therapies to fight HIV infection. Garira et al. [4] studied an optimal control problem including immune response and multidrug effects for HIV multitherapy enhancement. However, although most of the previous researches took the Cytotoxic T Lymphocytes (CTL) into account, they ignored the neutralizing antibodies, and very few studies have been carried out on comparing the outcomes before and after using antiviral drugs.

In this paper, we use numerical analysis and optimization tools to suggest improved therapies to try and cure HIV infection for an improved HIV model of ordinary differential equation, which includes immune response, neutralizing antibodies, and multidrug effects. We use two controls, one simulating effect of RTIs, and the other control simulating effect of PIs. We determine nine types of treatment strategies, which including single-drug controls and two-drug controls, based on different combinations of weight factor pairs combining with special upper-bound pairs for controls. The rest of this paper is organized as follows. In Section 2, an HIV model with antibody response is extended and an optimal control problem for HIV/AIDS is established. In Section 3, the existence of optimal control pair is investigated.

In Section 4, the optimal control pair (the optimality system) is derived by using Pontryagin's maximum principle [5–7]. In Section 5, some numerical results of optimal treatment policies are illustrated. In Section 6, we conclude by discussing the results of the numerical simulations based on different weight coefficients and upper-bounds for controls.

2. The Model

In 2005, an optimal control problem including immune response and multidrug effects for HIV multitherapy enhancement,

$$\max J = \int_0^{t_f} [T - (\alpha_1 u_1^2 + \alpha_2 u_2^2)] dt \quad (1)$$

$$\text{s.t.} \quad \begin{aligned} \dot{T} &= s_1 + \frac{r_1 TV}{B_V + V} - \mu_T T - (1 - u_1) k_1 T V e^{-a_0 E} \\ &\quad - \frac{r_2 TV}{B_T + T}, \end{aligned} \quad (2)$$

$$\dot{I} = (1 - u_1) k_1 T V e^{-a_0 E} - \mu_I I - k_3 I E, \quad (3)$$

$$\dot{V} = (1 - u_2) N \mu_I I e^{-a_1 E} - \mu_V V, \quad (4)$$

$$\dot{E} = s_2 + k_4 T V E - \mu_E E, \quad (5)$$

$$T(0), I(0), V(0), E(0) \geq 0, \quad 0 \leq u_1, u_2 \leq 1, \quad (6)$$

was studied by Garira et al. [4]. For a fixed time, a two-drug treatment strategy was obtained based on Pontryagin's minimum principle. The quadratic objective function considered takes into account two contributions: the viral load and the quantities of drug used. Simulations were carried out using an indirect optimization method. At each step the differential system was solved using Runge-Kutta five order scheme. Results highlighted that a progressive reduction of reverse transcriptase inhibitor (RTIs) drug dose on the one hand along with on the other hand a progressive increase of protease inhibitor (PIs) one was needed for optimality.

Garira et al. [4] take the cytotoxic T lymphocytes (CTL) into account, however, they ignore the neutralizing antibodies and latent period. The antibodies can combine with the virus such that the virus cannot get into target cells and protect a host against the infection by HIV-1. They can be induced several weeks after infection [8–11]. These facts mean that the neutralizing antibodies are important in the early stage of the infection. Because the antibodies are secreted by effector B cells, we add a term $B(t)$, which represents the concentration of effector B cells, to the control system. Since the differentiation and proliferation of B-cells to effector B-cells need the help of $CD4^+$ T-cells, we assume the generation rate is $k_5 VT$. A simple mass-action type of term will be used with rate constant k_5 . As HIV-1 mutates rapidly, the average term of validity of effector B-cells is shorter than normal, we multiply the death rate, μ_B , by a positive constant $\beta \geq 1$. Thus, the term $B(t)$ should satisfy the following equation:

$$\dot{B} = k_5 VT - \beta \mu_B B. \quad (7)$$

Because of the assumption that the antibodies' concentration is proportional to effector B cells' concentration, the neutralizing rate should be expressed by qBV and (4) should be modified to the following equation:

$$\dot{V} = (1 - u_2) N \mu_I I e^{-a_1 E} - \mu_V V - qBV. \quad (8)$$

Since viral DNA once integrated in cell nucleus, may remain dormant, in the latent stage, we also take the latent period into account as in [11, 12]. Furthermore, we assume that latently infected cells, which have not yet produced virus, switch to productively infected cell with rate k_2 . Let L be the concentration of latently infected $CD4^+$ T cells, then we have

$$\dot{L} = \omega (1 - u_1) k_1 T V e^{-a_0 E} - \mu_L L - k_2 L, \quad (9)$$

which implies that (3) should be modified to the following equation:

$$\dot{I} = (1 - \omega) (1 - u_1) k_1 T V e^{-a_0 E} + k_2 L - \mu_I I - k_3 I E, \quad (10)$$

where ω represents fraction of latently infected $CD4^+$ T cells in infected cells production, and so the term $\omega(1 - u_1)k_1 T V e^{-a_0 E}$ is added to L and $(1 - \omega)(1 - u_1)k_1 T V e^{-a_0 E}$ is added to I .

Thus, a new HIV treatment system is established as the following system:

$$\begin{aligned} \dot{T} &= s_1 + \frac{r_1 TV}{B_V + V} - \mu_T T - (1 - u_1) k_1 T V e^{-a_0 E} \\ &\quad - \frac{r_2 TV}{B_T + T}, \\ \dot{L} &= \omega (1 - u_1) k_1 T V e^{-a_0 E} - \mu_L L - k_2 L, \\ \dot{I} &= (1 - \omega) (1 - u_1) k_1 T V e^{-a_0 E} + k_2 L - \mu_I I - k_3 I E, \\ \dot{V} &= (1 - u_2) N \mu_I I e^{-a_1 E} - \mu_V V - qBV, \\ \dot{E} &= s_2 + k_4 T V E - \mu_E E, \\ \dot{B} &= k_5 TV - \beta \mu_B B, \\ T(0), I(0), V(0), E(0) &\geq 0, \quad 0 \leq u_1 \leq b_1, \\ 0 \leq u_2 \leq b_2, \quad 0 \leq b_1, b_2 &\leq 1, \end{aligned} \quad (11)$$

where T, L, I, V, E, B denote the concentration of uninfected $CD4^+$ T cells, latently infected $CD4^+$ T cells, actively infected cells, $CD4^+$ T cells, infectious viruses, cytotoxic lymphocytes effector, and B cells, respectively. Drugs efficiency is represented by the controls u_1 and u_2 which account for reverse transcriptase inhibitors and protease inhibitors actions, respectively.

This is a modification of model for HIV infection considered in Garira et al. [4]. In view of the importance of neutralizing antibody especially in the early stage of the infection, we add a term $B(t)$ as in Zhou et al. [11], which describes effector B cells, to the control system. We chose effector B cells as antibody response because the antibodies are secreted by effector B cells.

TABLE 1: Definitions and values for parameters.

Parameter	Constants	Values with unit
r_1	Rate growth of uninfected CD4 ⁺ T	0.01 d ⁻¹
r_2	Rate apoptosis of uninfected CD4 ⁺ T	2e - 3 d ⁻¹
B_V	Parameter involving amount of antigen	400
B_T	Parameter involving apoptosis of CD4 ⁺ T	350
μ_T	Death rate of uninfected CD4 ⁺ T	0.02 d ⁻¹
μ_I	Death rate of infected CD4 ⁺ T	0.25 d ⁻¹
μ_V	Death rate of virus	0.95 d ⁻¹
μ_E	Death rate of CTL	1.5 d ⁻¹
μ_B	Death rate of antibodies	0.005 d ⁻¹
q	Rate virus deleted by CTL	5e - 2 mm ³ d ⁻¹
k_1	Rate CD4 ⁺ T becomes infected by virus	2e - 4 mm ³ d ⁻¹
k_2	Rate latently infected convert to actively infected	3e - 3 mm ³ d ⁻¹
k_3	Rate actively infected cells deleted by CTL	2e - 3 mm ³ d ⁻¹
k_4	Rate growth of CTL	1e - 5 mm ³ d ⁻¹
k_5	Rate growth of antibody	2e - 4 mm ³ d ⁻¹
a_0	Efficiency of each CTL	0.01 d ⁻¹
a_1	Rate CTL suppresses virus	0.075 d ⁻¹
N	Average of viral particles	1000
s_1	Source term for uninfected CD4 ⁺ T	20 mm ³ d ⁻¹
s_1	Source term for CTL	10 mm ³ d ⁻¹
ω	Fraction of latently/infected CD4 ⁺ T	0.5
β	Multiple of death rate of antibodies	10

Uninfected cells are generated at a constant rate s_1 and are proliferated at the rate $r_1 TV/B_V + V$, where r_1 is the proliferation rate and B_V is a parameter that determines the amount of antigen needed to generate half maximal stimulation. Uninfected cells die at a rate of $\mu_T T$, implying that the average lifetime of an uninfected cell is $1/\mu_T$, and destruct at a rate of $r_2 TV/B_T + T$ due to the influence of toxic viral proteins, where r_2 is the rate of apoptosis and B_T is a parameter that determines the scale at which engagement of apoptosis receptors begins to take effect. Uninfected cells may become infected cells at a rate of $(1 - u_1)k_1 TVe^{-a_0 E}$, where k_1 is the rate of infection of CD4⁺T cells by virus and a_0 is the efficiency of each CTL in reducing CD4⁺T cells infection while u_1 represents efficiency of RTIs in blocking the recoding process. Infected cells die at a rate of $\mu_I I$, meaning that the average lifetime of an infected cell is $1/\mu_I$, and are lysed by CTLs at a rate of $k_2 IE$. Free infectious virus is replicated at a rate of $(1 - u_2)N\mu_I Ie^{a_1 E}$, where an average of N virus particles are released per infected cell and a_1 is the rate at which each CTL suppresses virus production while u_2 represents efficiency of PIs in reducing infection.

Using the method in [13] combined with the least square estimation, we fit the parameters q, k_5, β, μ_B keeping the rest of parameters in [4] unchanged; the fitting data comes from the literature [14]. We employ the data of patient 7 and patient 9 in [14] to estimate the parameters and get the range of the parameters q : 0.0089 - 0.0549, k_4 : 0.0038 - 0.000382, $\beta\mu_B$ = 0.4104 - 0.0506.

Thus, definitions and values of the parameters used in this model are given in Table 1 (see also [4] with references for old parameters).

Our objective functional is also defined as

$$J(u_1, u_2) = \int_{t_0}^{t_f} [T - (\alpha_1 u_1^2 + \alpha_2 u_2^2)] dt. \quad (12)$$

The first term represents the benefit of T cells and other terms are systemic costs of drug treatments. The positive constants α_1 and α_2 balance the size of the terms, and u_1^2, u_2^2 reflect the severity of the side effects of the drugs. We seek an optimal control pair, u_1^*, u_2^* , such that

$$J(u_1^*, u_2^*) = \max_{0 \leq u_1 \leq b_1, 0 \leq u_2 \leq b_2} J(u_1, u_2). \quad (13)$$

3. Existence of an Optimal Control Pair

Theorem 1. *For the control problem (11), there exists an optimal control pair (u_1^*, u_2^*) that maximizes the objective functional $J(u_1, u_2)$.*

Proof. To use an existence result, Theorem III.4.1 from [15], we must check the following properties.

- (1) The set of controls and corresponding state variables is nonempty.
- (2) The control U set is convex and closed.

FIGURE 1: Optimal solutions only using PIs with sufficiently small weight coefficient α_2 for a 50-day treatment.

- (3) The right hand side of the state system is bounded by a linear function in the state and control variables.
- (4) The integrand of the objective functional is concave on U .
- (5) There exist constants $c_1, c_2 > 0$ and $b > 1$ such that the integrand of the objective functional is bounded above by

$$c_2 - c_1(|u_1|^2 + |u_2|^2)^{b/2}. \quad (14)$$

First, an existence result in Lukes ([16], Theorem 9.2.1) for the control system (11) for bounded coefficients is invoked, which gives condition 1. The control set $U = \{(u_1, u_2) : 0 \leq u_1 \leq b_1, 0 \leq u_2 \leq b_2\}$ is closed and convex by definition. Since the control system is bilinear in u_1, u_2 , the right hand side of (11) satisfies condition 3, using the boundedness of the solutions obtained by the analytical method in [17]. Note that the integrand of the objective functional is concave on

the admissible control set U . Also we have the last condition needed

$$T - (\alpha_1 u_1^2 + \alpha_2 u_2^2) \leq c_2 - c_1(|u_1|^2 + |u_2|^2)^{b/2}, \quad (15)$$

where c_2 depends on the upper-bound on T and $c_1 > 0$ since $\alpha_1, \alpha_2 > 0$. We conclude that there exists an optimal control pair. This completes the proof. $\square$

4. Optimality System

Denote Hamiltonian $H(T, L, I, V, E, B; u_1, u_2; \lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5, \lambda_6)$ as

$$H = T - (\alpha_1 u_1^2 + \alpha_2 u_2^2) + \lambda_1 \left(s_1 + \frac{r_1 TV}{B_V + V} - \mu_T T - (1 - u_1) k_1 T V e^{-a_0 E} \right)$$

FIGURE 2: Optimal solutions only using PIs with sufficiently large weight coefficient α_2 for a 50-day treatment.

$$\begin{aligned}
 & -\frac{r_2 TV}{B_T + T} \Big) \\
 & + \lambda_2 \left(\omega (1 - u_1) k_1 T V e^{-a_0 E} - \mu_T L - k_2 L \right) \\
 & + \lambda_3 \left((1 - \omega) (1 - u_1) k_1 T V e^{-a_0 E} + k_2 L - \mu_I I - k_3 I E \right) \\
 & + \lambda_4 \left((1 - u_2) N \mu_I I e^{-a_1 E} - \mu_V V - q B V \right) \\
 & + \lambda_5 (s_2 + k_4 T V E - \mu_E E) \\
 & + \lambda_6 (k_5 T V - \beta \mu_B B),
 \end{aligned} \tag{16}$$

where λ_i ($i = 1, 2, \dots, 6$) are costate variables. By Pontryagin's maximum principle, we have the following Theorem.

Theorem 2. If u_1^*, u_2^* are optimal controls of the optimal control problem (11)–(13), $T^*, L^*, I^*, V^*, E^*, B^*$ are the corresponding optimal paths, then there exist costate variables λ_i ($i = 1, 2, \dots, 6$) such that, besides the fact that control system (11) is satisfied, the following conditions are satisfied:

(i) costate equations:

$$\begin{aligned}
 \dot{\lambda}_1 &= -\frac{\partial H}{\partial T} \\
 &= -1 + \lambda_1 \left[\mu_T + (1 - u_1) k_1 V e^{-a_0 E} \right.
 \end{aligned}$$

$$\left. -\frac{r_1 V}{B_V + V} + \frac{r_2 B_T V}{(B_T + T)^2} \right]$$

FIGURE 3: Optimal solutions only using RTIs with sufficiently large weight coefficient α_1 for a 50-day treatment.

$$\begin{aligned}
 & -(\omega\lambda_2 + (1-\omega)\lambda_3)(1-u_1)k_1Ve^{-a_0E} \\
 & -\lambda_5k_4VE - \lambda_6k_5V, \\
 \dot{\lambda}_2 &= -\frac{\partial H}{\partial L} = (\mu_T + k_2)\lambda_2 - k_2\lambda_3, \\
 \dot{\lambda}_3 &= -\frac{\partial H}{\partial I} \\
 &= \lambda_3(\mu_I + k_3E) - \lambda_4(1-u_2)N\mu_Ie^{-a_1E}, \\
 \dot{\lambda}_4 &= -\frac{\partial H}{\partial V} \\
 &= \lambda_1 \left[(1-u_1)k_1Te^{-a_0E} + \frac{r_2T}{B_T+T} - \frac{r_1B_VT}{(B_V+V)^2} \right] \\
 & -(\omega\lambda_2 + (1-\omega)\lambda_3)(1-u_1)k_1Te^{-a_0E} \\
 & + \lambda_4(\mu_V + qB) - \lambda_5k_4TE - \lambda_6k_5T, \\
 \dot{\lambda}_5 &= -\frac{\partial H}{\partial E} = (\omega\lambda_2 - \lambda_1)a_0(1-u_1)k_1TVe^{-a_0E} \\
 & + \lambda_3(a_0(1-\omega)(1-u_1)k_1TVe^{-a_0E} + k_3I) \\
 & + \lambda_4a_1(1-u_2)N\mu_Ie^{-a_1E} + \lambda_5(\mu_E - k_4TV), \\
 \dot{\lambda}_6 &= -\frac{\partial H}{\partial B} = \lambda_4qV + \lambda_6\beta\mu_B;
 \end{aligned} \tag{17}$$

(ii) optimality conditions:

$$\begin{aligned}
 & H(T^*, L^*, I^*, V^*, E^*, B^*; u_1^*, u_2^*; \lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5, \lambda_6) \\
 &= \max_{0 \leq u_i \leq b_i, i=1,2} H(T^*, L^*, I^*, V^*, E^*, B^*; u_1, u_2; \\
 & \quad \lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5, \lambda_6),
 \end{aligned} \tag{18}$$

FIGURE 4: Optimal solutions only using RTIs with sufficiently small weight coefficient α_1 for a 50-day treatment.

which imply that

$$\begin{aligned}
 u_1^* &= \min \left\{ b_1, \max \left\{ \frac{(\lambda_1 - \omega \lambda_2 - (1 - \omega) \lambda_3) k_1 T^* V^* e^{-a_0 E^*}}{2\alpha_1}, 0 \right\} \right\}, \\
 u_2^* &= \min \left\{ b_2, \max \left\{ -\frac{\lambda_4 N \mu_I I^* e^{-a_1 E^*}}{2\alpha_2}, 0 \right\} \right\}; \quad (19)
 \end{aligned}$$

(iii) transversality conditions:

$$\lambda_i(t_f) = 0, \quad i = 1, 2, \dots, 6. \quad (20)$$

The optimality system consists of control system (11) coupled with the costate equation (17) with the initial conditions and transversality conditions together with the characterization of the optimal control pair (19).

Remark 3. Using similar method in [11], we can obtain the uniqueness of solution to the above optimality system when t_f is sufficiently small. We omit it

5. Numerical Illustration

Analytical solutions for optimal control are difficult to obtain since the system is nonlinear. In this section, we use gradient

FIGURE 5: Optimal solutions using RTIs and PIs with $\alpha_1 \gg \alpha_2$ for a 50-day treatment.

projection method to solve the optimal control problem numerically for an intuitive solution. The ODE is discrete with Euler discrete format and the costate equations of the recurrence equations produced by discretization are employed to calculate the gradient. The dynamic systems response is exactly computed with adjusted control history from one iteration to the next to increase objective function at each step. The iterations continue until convergence is achieved. The convergence criterion is the norm of the gradient projection on feasible control field. The convergence rate of this method is slow, but it is convergent in the problem of this paper.

Linked to the work in [4], we set the initial conditions $T(0) = 250$, $L(0) = 100$, $I(0) = 200$, $V(0) = 4000$, $E(0) = 100$, $B(0) = 50 \text{ mm}^{-3}$, weight factors (α_1, α_2) are the combinations of 125000 and 125, and the drug doses are up bounded by $b_1 = 0.002$ and $b_2 = 0.9$, respectively, a limitation is for the purpose of exploring optimal chemotherapy treatment to avoid an excessive use of drugs as indeed when these drugs are

administered in high dose they are toxic to the human body and cause damage. We choose a 50-day treatment period in keeping with what is in [4] on treatment of HIV/AIDS. In the following sections, we will only draw the paths of uninfected CD4^+ T-cells T and virus particles V , because people may be more interested in the number of uninfected CD4^+ T-cells and virus particles rather than other cells in clinical practice. Also, we will plot the path relative to T or V without any control at each drawing for comparing the treatment effect before and after the chemotherapy is introduced. This paper will illustrate nine cases for different combinations of the weight factors pairs (α_1, α_2) combining with two kinds of upper-bounds b_1 for a 50-day treatment schedule. These strategies include:

- (i) Strategy I: only use of PIs with sufficiently small α_2 ;
- (ii) Strategy II: only use of PIs with sufficiently large α_2 ;

FIGURE 6: Optimal solutions using RTIs and PIs with sufficiently small $\alpha_1 \approx \alpha_2$ for a 50-day treatment.

- (iii) Strategy III: only use of RTIs with sufficiently large α_1 and smaller b_1 ;
- (iv) Strategy IV: only use of RTIs with sufficiently small α_1 and smaller b_1 ;
- (v) Strategy V: use both RTIs and PIs with $\alpha_1 \gg \alpha_2$ and smaller b_1 ;
- (vi) Strategy VI: use both RTIs and PIs with sufficiently small $\alpha_1 \approx \alpha_2$ and smaller b_1 ;
- (vii) Strategy VII: use both RTIs and PIs with $\alpha_1 \ll \alpha_2$ and smaller b_1 ;
- (viii) Strategy VIII: use both RTIs and PIs with sufficiently large $\alpha_1 \approx \alpha_2$ and smaller b_1 ;
- (ix) Strategy IX: use both RTIs and PIs with sufficiently small $\alpha_1 \approx \alpha_2$ and larger b_1 .

Remark 4. The extra Strategy IX is considered to compare the different treatment effects for the two-drug strategies with similar weight factors, but with different upper-bounds for the control u_1 .

Let $u_1 \equiv 0$ and let $\alpha_2 = 125$, then we can get the optimal treatment policy with single PIs, that is, Strategy I. Figure 1 is plotted by using $\alpha_1 = 0$, $\alpha_2 = 125$, $b_1 = 0$, and $b_2 = 0.9$ and keeping the rest of the parameters unchanged. The number of uninfected CD4⁺T-cells T in Figure 1 is obviously higher than one without any control, while the number of virus particles V is evidently lower than one without any control about 4 days after beginning therapy, which implies that the treatment only using PIs with sufficiently small weight coefficient can effectively improve the patients' condition although the treatment effect begins to reduce from the 41th day. The optimal drug administration schedule of PIs is with

FIGURE 7: Optimal solutions using RTIs and PIs with $\alpha_1 \ll \alpha_2$ for a 50-day treatment.

maximal effort for a longer period of about 38 days (4th–41th day), but with almost no treatment in the other times including initial stages and final stages.

Figure 2 is plotted using $\alpha_1 = 0$, $\alpha_2 = 125000$, $b_1 = 0$, and $b_2 = 0.9$, and keeping the rest of parameters unchanged under the assumption of $u_1 \equiv 0$. Figure 2 represents the treatment policy only using PIs with sufficiently large weight coefficient, that is, Strategy II. The optimal schedule recommends that the dose of PIs is extremely low (less than 0.00035). But, the dynamics of uninfected $CD4^+$ T-cells T and active virus V in Figure 2 hints no improvement for treatment. In other words, Strategy II is not useful for the therapy of HIV/AIDS.

Figure 3 is plotted by using $\alpha_1 = 125000$, $\alpha_2 = 0$, $b_1 = 0.002$, and $b_2 = 0$, and keeping the rest of parameters unchanged under the assumption of $u_2 \equiv 0$. Figure 3 represents the treatment policy only using RTIs with sufficiently large weight coefficient, that is, Strategy III. The optimal schedule recommends that the dose of RTIs is decreasing.

But, the dynamics of uninfected $CD4^+$ T-cells T and active virus V in Figure 3 means no improvement for treatment.

Figure 4 is plotted by using $\alpha_1 = 125$, $\alpha_2 = 0$, $b_1 = 0.002$, and $b_2 = 0$, and keeping the rest of parameters unchanged under the assumption of $u_2 \equiv 0$. Figure 4 represents the treatment policy only using RTIs with sufficiently small weight coefficient, that is, Strategy IV. The dynamics of uninfected $CD4^+$ T-cells T and active virus V in Figure 4 implies no improvement for treatment, though the maximal effort for control is needed.

Figure 5 is plotted by using $\alpha_1 \gg \alpha_2$ (for instance, $\alpha_1 = 125000$ and $\alpha_2 = 125$), $b_1 = 0.002$, and $b_2 = 0.9$, and keeping the rest of the parameters unchanged. Figure 5 represents Strategy V and shows that the number of uninfected $CD4^+$ T-cells T is obviously added, while the number of virus particles V is evidently reduced about 4 days after beginning therapy. The optimal schedule recommends that the dose of RTIs is extremely low (majority less than 0.0005) and in the opposite

FIGURE 8: Optimal solutions using RTIs and PIs with sufficiently large $\alpha_1 \approx \alpha_2$ for a 50-day treatment.

PIs is used with maximal effort during its valid term (4th–41th day).

Figure 6 is plotted using sufficiently small $\alpha_1 \approx \alpha_2$ (for instance, $\alpha_1 = 125$ and $\alpha_2 = 125$), $b_1 = 0.002$, and $b_2 = 0.9$, and keeping the rest of the parameters unchanged. Figure 6 represents Strategy VI and gives the similar results as Strategy V. But the optimal schedule recommends that the dose of RTIs is used with maximal effort during almost whole treatment period and PIs is used with maximal effort during its valid treatment term (4th–41th day).

Figure 7 is plotted using $\alpha_1 \ll \alpha_2$ (for instance, $\alpha_1 = 125$ and $\alpha_2 = 125000$), $b_1 = 0.002$, and $b_2 = 0.9$, and keeping the rest of the parameters unchanged. Figure 7 represents Strategy VII and shows that the number of uninfected $CD4^+$ T-cells T is not yet added, while the number of virus particles V is not yet reduced though two-drug treatment has been implemented during whole therapy period. This means that the Strategy VII is not at all helping the therapy of HIV/AIDS.

Figure 8 is plotted using sufficiently large $\alpha_1 \approx \alpha_2$ (for instance, $\alpha_1 = 125000$ and $\alpha_2 = 125000$), $b_1 = 0.002$, and $b_2 = 0.9$, and keeping the rest of the parameters unchanged. Figure 8 represents Strategy VIII and gives a similar ineffective-treatment result as Strategy VII, although two-drug treatment is implemented.

Remark 5. From Figures 1–8, we find that no strategies except Strategy I, Strategy V, and Strategy VI are very helpful for the therapy of HIV/AIDS, which means that all of the single-drug treatment strategies with RTIs are ineffective, or at least are not very effective. These theoretical evidences also show the fact that using a single RTIs is not an effective clinical strategy for therapy of HIV/AIDS.

Remark 6. We also find that the treatment policies with sufficient large weight coefficients are all useless, or at least are not particularly helpful, which implies that high costs may have critical implications for the treatment of HIV.

FIGURE 9: Optimal solutions using RTIs and PIs with sufficiently small $\alpha_1 \approx \alpha_2$ and bigger upper-bound b_1 for a 50-day treatment.

Moreover, among the strategies with effective treatment, the treatment effect using Strategy V and Strategy VI (with two-drug control) seems similar as the one using Strategy I (with single-drug control (PIs)). Is it really true? When the upper-bound b_1 for control u_1 in the strategies with two-drug treatment is added (a hundredfold, for instance), the Strategy VI can get better treatment effect than the Strategy I, which implies that two-drug control strategy with small weight factors, when RTIs are improved but PIs unchanged, is more effective than single-drug control strategy with PIs. Figure 9 (Strategy IX) illustrates this case. But, whatever the upper-bound b_1 is, the treatment effect using Strategy V (with large weight factor for RTIs) is almost consistent with the one using Strategy I, which shows, again, that large weight factor (i.e., high cost) may counteract treatment effect.

Remark 7. Comparing, respectively, the maximal value of T (608) and the minimal value of V (40) in Figure 6 with the maximal value of T (620) and the minimal value of V (21) in Figure 9, we find that the treatment effect for the strategy using both RTIs and PIs with sufficiently small weight factors has not gotten remarkably improved even after the upper-bound b_1 for the control u_1 is increased a hundredfold. This implies that only increasing dosage of RTIs for the effective two-drug control strategies cannot markedly improve the patient's health condition.

Remark 8. Overall, Strategy V, Strategy VI, and Strategy IX show that combined treatment such as above two-drug therapy is more effective than single-drug cure. This fact may help to explain why the HAARP is still the most effective method for therapy of HIV/AIDS till now.

6. Conclusion and Discussion

In this research, a deterministic HIV model including immune response, neutralizing antibodies, and multidrug effects is improved. Optimization theories are used to derive optimal control solution and to design improved clinical treatments. The existence for the optimal control problem is proved, the optimality system is derived, and a gradient projection method is applied to numerically simulate different therapy effects. On the basis of combinations of weight factors and upper-bounds for controls, we establish some of much interesting or even strange treatment strategies including four types of single-drug controls and five types of two-drug controls, where a large weight coefficient means a high cost of the corresponding drug. Among the nine strategies, no strategy except the Strategy I, Strategy V, Strategy VI, and Strategy IX is helpful for the therapy of HIV/AIDS, which means that the single-drug treatment with RTIs is ineffective for treating HIV/AIDS, or at least is not very effective. These theoretical evidences also show the fact that using a single RTIs is not an effective clinical strategy for therapy of HIV/AIDS. We also find that the treatment policies with higher cost are not useful, or at least are not particularly helpful. Among those strategies with effective treatment, the policy using two-drug control with lower cost should be the best clinical one because it can more efficiently increase the number of uninfected $CD4^+$ T-cells and decrease the number of virus particles. And, overall, combined treatment is more effective than single-drug cure. This fact may help to explain why the HAARP is always regarded as the most effective method for therapy of HIV/AIDS.

But, why can the larger weight factor counteract the use of drug? Is it possible that, as indicated by Figure 2 and Figure 8, the higher cost results in the lower dosage of drug? For the effective two-drug treatment policies, why has the treatment effect not gotten markedly improved even after the dosage of RTIs is increased manyfold? Further researches need to be done in the future.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This research was supported by the Natural Science Foundation of China (11271371) (71272209), and the Humanity and Social Science Foundation of Ministry of Education of China (12YJA630170), and the Natural Science Foundation of Hunan Province (12JJ3081). Thank are due to the reviewer's comments for this paper.

References

- [1] B. M. Adams, H. T. Banks, H. Kwon, and H. T. Tran, "Dynamic multidrug therapies for HIV: optimal and STI control approaches," *Mathematical Biosciences and Engineering*, vol. 1, no. 2, pp. 223–241, 2004.
- [2] R. Zurakowski and A. R. Teel, "A model predictive control based scheduling method for HIV therapy," *Journal of Theoretical Biology*, vol. 238, no. 2, pp. 368–382, 2006.
- [3] J. Karrakchou, M. Rachik, and S. Gourari, "Optimal control and infectiology: application to an HIV/AIDS model," *Applied Mathematics and Computation*, vol. 177, no. 2, pp. 807–818, 2006.
- [4] W. Garira, S. D. Musekwa, and T. Shiri, "Optimal control of combined therapy in a single strain HIV-1 model," *Electronic Journal of Differential Equations*, vol. 2005, no. 52, pp. 1–22, 2005.
- [5] D. Hull, *Optimal Control Theory for Applications*, Springer, New York, NY, USA, 2003.
- [6] M. I. Kamien and N. L. Schwartz, *Dynamic Optimization: The Calculus of Variations and Optimal Control in Economics and Management*, Advanced Textbooks in Economics, North-Holland Press, Amsterdam, Netherlands, 1991.
- [7] L. S. Pontryagin, *Mathematical Theory of Optimal Processes*, CRC Press, Boca Raton, Fla, USA, 1987.
- [8] Y. Lin and P. Zhong, "Impact, mechanism and laboratory detection of neutralizing antibody in HIV-1," *Chinese Journal of AIDS & STD*, vol. 14, no. 6, pp. 634–636, 2008 (Chinese).
- [9] J. S. McLellan, M. Pancera, C. Carrico et al., "Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9," *Nature*, vol. 480, no. 7377, pp. 336–343, 2011.
- [10] C. Ren, Y. Li, and H. Ling, "Neutralizing antibodies responses during natural HIV-1 infection," *International Journal of Immunology*, vol. 3, no. 35, pp. 176–179, 2012 (Chinese).
- [11] Y. Zhou, Y. Liang, and J. Wu, "An optimal strategy for HIV multitherapy," *Journal of Computational and Applied Mathematics*, vol. 263, pp. 326–337, 2014.
- [12] J. M. Orellana, "Optimal control for HIV multitherapy enhancement," *Comptes Rendus Mathématique*, vol. 348, pp. 1179–1183, 2011.
- [13] H. Wu, H. Zhu, H. Miao, and A. S. Perelson, "Parameter identifiability and estimation of HIV/AIDS dynamic models," *Bulletin of Mathematical Biology*, vol. 70, no. 3, pp. 785–799, 2008.
- [14] M. A. Stafford, L. Corey, Y. Cao, E. S. Daar, D. D. Ho, and A. S. Perelson, "Modeling plasma virus concentration during primary HIV infection," *Journal of Theoretical Biology*, vol. 203, no. 3, pp. 285–301, 2000.
- [15] W. H. Fleming and R. W. Rishel, *Deterministic and Stochastic Optimal Control*, Springer, New York, NY, USA, 1975.
- [16] D. L. Lukes, "Differential equations: classical to controlled," in *Mathematics in Science and Engineering*, Academic Press, New York, NY, USA, 1982.
- [17] A. S. Perelson, D. E. Kirschner, and R. D. Boer, "Dynamics of HIV infection of $CD4^+$ T cells," *Mathematical Biosciences*, vol. 114, no. 1, pp. 81–125, 1993.